Journal of Clinical Endocrinology & Metabolism, Vol 71, 566-574, Copyright © 1990 by Endocrine Society

ARTICLES

Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy

SW Lamberts, LJ Hofland, PM van Koetsveld, JC Reubi, HA Bruining, WH Bakker and EP Krenning
Department of Medicine, Erasmus University, Rotterdam, The Netherlands.

The effects of octreotide in vivo and in vitro on hormone release, in vivo [123I]Tyr3-octreotide scanning, and in vitro [125I]Tyr3-octreotide autoradiography were compared in five patients with endocrine pancreatic tumors. [123I]Tyr3-octreotide scanning localized the primary tumor and/or previously unknown metastases in four of the five patients. The patient with a negative scan had an insulinoma that did not respond to octreotide in vivo. No Tyr3-octreotide-binding sites were subsequently found at autoradiography of the tumor, whereas somatostatin-14 receptors were present at a high density. In parallel, culture studies with the cells prepared from this adenoma showed that insulin release was not affected by octreotide, while both somatostatin- 14 and -28 significantly suppressed hormone release. Culture studies of the tumor cells from two gastrinomas showed a dose-dependent inhibition of gastrin release by octreotide. Octreotide exerted direct antiproliferative effects in one of these gastrinomas, which had been shown to be rapidly growing in vivo. Both gastrinomas had specific somatostatin receptors, as measured by in vitro receptor autoradiography. Somatostatin release by the cultured somatostatinoma cells from one of these patients was suppressed by octreotide. In conclusion, 1) the [123I]Tyr3-octreotide scanning procedure is valuable in the localization of primary endocrine pancreatic tumors as well their often clinically not yet recognized metastases; 2) the in vitro detection of somatostatin receptors in those tumors that were also visualized in vivo after injection of [123I] Tyr3-octreotide indicates that the ligand binding to the tumor in vivo indeed represents binding to specific somatostatin receptors; and 3) the parallel between the presence of somatostatin receptors on tumors and in in vivo and in vitro effects of octreotide on hormonal release from these tumors indicate that a positive scan predicts a good suppressive effect of octreotide on hormonal hypersecretion by these tumors.

This article has been cited by other articles:

				D. O'Toole, A. Saveanu, A. Couvelard, G. Gunz, A. Enjalbert, P. Jaquet, P. Ruszniewski, and A. Barlier The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies Eur. J. Endocrinol., December 1, 2006; 155(6): 849 - 857. [Abstract] [Full Text] [PDF]

				D. Vezzosi, A. Bennet, P. Rochaix, F. Courbon, J. Selves, B. Pradere, L. Buscail, C. Susini, and P. Caron Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies Eur. J. Endocrinol., May 1, 2005; 152(5): 757 - 767. [Abstract] [Full Text] [PDF]

				A. SUNDIN, B. ERIKSSON, M. BERGSTROM, B. LANGSTROM, K. OBERG, and H. ORLEFORS PET in the Diagnosis of Neuroendocrine Tumors Ann. N.Y. Acad. Sci., April 1, 2004; 1014(1): 246 - 257. [Abstract] [Full Text] [PDF]

				M. Gabriel, C. Decristoforo, E. Donnemiller, H. Ulmer, C. Watfah Rychlinski, S. J. Mather, and R. Moncayo An Intrapatient Comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-Octreotide for Diagnosis of Somatostatin Receptor-Expressing Tumors J. Nucl. Med., May 1, 2003; 44(5): 708 - 716. [Abstract] [Full Text] [PDF]

				O. Schillaci, A. Spanu, F. Scopinaro, A. Falchi, R. Danieli, P. Marongiu, N. Pisu, G. Madeddu, G. Delle Fave, and G. Madeddu Somatostatin Receptor Scintigraphy in Liver Metastasis Detection from Gastroenteropancreatic Neuroendocrine Tumors J. Nucl. Med., March 1, 2003; 44(3): 359 - 368. [Abstract] [Full Text] [PDF]

				L. J. Hofland and S. W. J. Lamberts The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance Endocr. Rev., February 1, 2003; 24(1): 28 - 47. [Abstract] [Full Text] [PDF]

				R. Lebtahi, J. Le Cloirec, C. Houzard, D. Daou, I. Sobhani, G. Sassolas, M. Mignon, P. Bourguet, and D. Le Guludec Detection of Neuroendocrine Tumors: 99mTc-P829 Scintigraphy Compared with 111In-Pentetreotide Scintigraphy J. Nucl. Med., July 1, 2002; 43(7): 889 - 895. [Abstract] [Full Text] [PDF]

				H Kulaksiz, R Eissele, D Rossler, S Schulz, V Hollt, Y Cetin, and R Arnold Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies Gut, January 1, 2002; 50(1): 52 - 60. [Abstract] [Full Text] [PDF]

				U Hesse, D Ysebaert, and B de Hemptinne Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data Gut, December 1, 2001; 49(90004): iv11 - 20. [Abstract] [Full Text] [PDF]

				L. J. Hofland, W. W. de Herder, M. Waaijers, J. Zuijderwijk, P. Uitterlinden, P. M. van Koetsveld, and S. W. J. Lamberts Interferon-{alpha}-2a Is a Potent Inhibitor of Hormone Secretion by Cultured Human Pituitary Adenomas J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3336 - 3343. [Abstract] [Full Text]

				L. J. Hofland, W. W. de Herder, H. A. Visser-Wisselaar, C. van Uffelen, M. Waaijers, J. Zuyderwijk, P. Uitterlinden, M. J. M. Kros, P. M. van Koetsveld, and S. W. J. Lamberts Dissociation between the Effects of Somatostatin (SS) and Octapeptide SS-Analogs on Hormone Release in a Small Subgroup of Pituitary- and Islet Cell Tumors J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3011 - 3018. [Abstract] [Full Text] [PDF]